{"denoms":[{"counts":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"125"},{"groupId":"BG002","value":"251"}],"units":"Participants"}],"groups":[{"description":"Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"BG000","title":"Pembrolizumab+Pomalidomide+Dexamethasone"},{"description":"Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.","id":"BG001","title":"Standard of Care (SOC) Pomalidomide+Dexamethasone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.3","value":"65.5"},{"groupId":"BG001","spread":"10.0","value":"66.4"},{"groupId":"BG002","spread":"9.6","value":"65.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"94"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"157"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"110"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"227"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"11"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"29"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"24"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"187"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"216"}],"title":"Refractory to Lenalidomide"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"35"}],"title":"Sensitive to Lenalidomide"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Status (Refractory vs. Sensitive to Lenalidomide)","unitOfMeasure":"Participants"}],"populationDescription":"The analysis population included all randomized participants."}